Evaluation of serum IL-23 in multiple sclerosis in Iraqi patients

Abstract

Background/aim:A chronic neuroinflammation of disease with unknown cause and variable clinical development is multiple sclerosis (MS).Interleukin-23 (IL-23) is a constituent of the IL-12 cytokine family that has shown through development of T helper type 17 (Th17) cells development could play a chief role in the inflammatory autoimmune responses in multiple sclerosis (MS).Objective:A goal of studyis to assess IL-23 level in serum in Iraqi patients with multiple sclerosis (MS) in comparison with healthycontrol group.Methods:blood sampleswere taken from 45patients with multiple sclerosis and 30 healthy controls. IL-23 level in the serum wasassessed by Enzyme-Linked immunosorbent assay (ELISA).Results:: IL-23 level in the serum taken from affected persons was found to be significantly hiegher than its level in the serum of control group (P<0.05). We also observed significantlyhigher IL-23 serumlevels in females than males within patients group (P. Value=0.0349).Conclusions:Theresults show the increasinglevel ofIL-23 in patients with multiple sclerosis which confirms a role for IL-23 in MSsuggestedcould be a particularbiomarker and thecurative goalin MS therapythrough inhibiting.